Laura Mansi

Besancon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Journal: Expert opinion on investigational drugs

Published: June 08, 2026

Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France.

Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in France.

Journal: Cancers

Published: January 22, 2026

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.

Journal: Breast (Edinburgh, Scotland)

Published: August 26, 2025

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors.

Efficacy of everolimus in patients with hormone receptor positive, HER2 negative, metastatic breast cancer pretreated with CDK4/6 inhibitors.

Journal: Breast cancer research : BCR

Published: March 10, 2025

Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.

Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.

Journal: Breast cancer research : BCR

Published: August 26, 2024

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Journal: Future oncology (London, England)

Published: August 19, 2024

Postcancer rehabilitation: multidisciplinary exercise - programme organisation and feasibility.

Postcancer rehabilitation: multidisciplinary exercise - programme organisation and feasibility.

Journal: BMJ supportive & palliative care

Published: July 01, 2024

Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer.

Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: March 09, 2024

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Journal: Nature communications

Published: December 12, 2023

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Journal: Nature communications

Published: July 27, 2023

A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.

A randomized trial to evaluate the effects of a supervised exercise program on insomnia in patients with non-metastatic breast cancer undergoing chemotherapy: design of the FATSOMCAN study.

Journal: BMC cancer

Published: April 11, 2023

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Journal: BMJ oncology

Published: February 24, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026